報價延遲最少15分鐘:2025/07/17 07:44 EDT
盤前時段
|
||||
|
27.9 
|
|
|
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.36/-2.59
|
|
企業價值
1.55B
|
| 資產負債 |
|
每股賬面淨值
17.11
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
10.59M
|
|
每股收益
0.14
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
報價延遲最少15分鐘：2025/07/17 07:44 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T CellEngagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with atumor antigen-binding domain and a costimulatory CD28 binding domain. |
